CoChat

Developing New Treatments for Heart Failure: Focus on the Heart

Open access
Gheorghiade, Mihai, Larson, Christopher J., Shah, Sanjiv J., Greene, Stephen J., Cleland, John G.F., Colucci, Wilson S., Dunnmon, Preston, Epstein, Stephen E., Kim, Raymond J., Parsey, Ramin V., Stockbridge, Norman, Carr, James, Dinh, Wilfried, Krahn, Thomas, Kramer, Frank, Wahlander, Karin, Deckelbaum, Lawrence I., Crandall, David, Okada, Shunichiro, Senni, Michele, Sikora, Sergey, Sabbah, Hani N., Butler, Javed · 2016 · Circulation: Heart Failure
Cited by 64

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Compared with heart failure (HF) care 20 to 30 years ago, there has been tremendous advancement in therapy for ambulatory HF with reduced ejection fraction with the use of agents that block maladaptive neurohormonal pathways. However, during the past decade, with few notable exceptions, the frequency of successful drug development programs has fallen as most novel therapies have failed to offer incremental benefit or raised safety concerns (ie, hypotension). Moreover, no therapy has been approved specifically for HF with preserved ejection fraction or for worsening chronic HF (including acutely decompensated HF). Across the spectrum of HF, preliminary results from many phase II trials have been promising but are frequently followed by unsuccessful phase III studies, highlighting a disconnect in the translational process between basic science discovery, early drug development, and definitive clinical testing in pivotal trials. A major unmet need in HF drug development is the ability to identify homogeneous subsets of patients whose underlying disease is driven by a specific mechanism that can be targeted using a new therapeutic agent. Drug development strategies should increasingly consider therapies that facilitate reverse remodeling by directly targeting the heart itself rather than strictly focusing on agents that unload the heart or target systemic neurohormones. Advancements in cardiac imaging may allow for more focused and direct assessment of drug effects on the heart early in the drug development process. To better understand and address the array of challenges facing current HF drug development, so that future efforts may have a better chance for success, the Food and Drug Administration facilitated a meeting on February 17, 2015, which was attended by clinicians, researchers, regulators, and industry representatives. The following discussion summarizes the key takeaway dialogue from this meeting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circheartfailure.115.002727

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 64

Metadata

Authors
Gheorghiade, M., Larson, C. J., Shah, S. J., Greene, S. J., Cleland, J. G. F., Colucci, W. S., Dunnmon, P., Epstein, S. E., Kim, R. J., Parsey, R. V., Stockbridge, N., Carr, J., Dinh, W., Krahn, T., Kramer, F., Wahlander, K., Deckelbaum, L. I., Crandall, D., Okada, S., Senni, M., Sikora, S., Sabbah, H. N., & Butler, J.
Venue
Circulation: Heart Failure
Published
2016-05
Volume
9
Issue
5
ISSN
  • 1941-3289 (ISSN-L)
  • 1941-3297
OpenAlex
W2546982088
Cited by
64
References
4
FWCI
8.22
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Developing New Treatments for Heart Failure: Focus on the Heart. https://app.cochat.ai/papers/10.1161/circheartfailure.115.002727
The paper
Gheorghiade, M., Larson, C. J., Shah, S. J., Greene, S. J., Cleland, J. G. F., Colucci, W. S., Dunnmon, P., Epstein, S. E., Kim, R. J., Parsey, R. V., Stockbridge, N., Carr, J., Dinh, W., Krahn, T., Kramer, F., Wahlander, K., Deckelbaum, L. I., Crandall, D., Okada, S., . . . Butler, J. (2016). Developing New Treatments for Heart Failure: Focus on the Heart. Circulation: Heart Failure. https://doi.org/10.1161/circheartfailure.115.002727

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.